drugset / Trial / NCT00605644
Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain
Phase 2
Completed
128 enrolled
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects administered MOA-728 who have chronic pain that is not due to cancer, and who have opioid-induced bowel dysfunction (OIBD).
Timeline
- Start
- 2008-01
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylnaltrexone | Other / unclassified | 150 mg | Oral |
| Subject | Methylnaltrexone | Other / unclassified | 300 mg | Oral |
| Subject | Methylnaltrexone | Other / unclassified | 450 mg | Oral |
| Subject | Methylnaltrexone | Other / unclassified | 600 mg | Oral |